Adaptive Biotechnologies Corp
NASDAQ:ADPT

Watchlist Manager
Adaptive Biotechnologies Corp Logo
Adaptive Biotechnologies Corp
NASDAQ:ADPT
Watchlist
Price: 4.69 USD 7.32% Market Closed
Market Cap: 692.2m USD
Have any thoughts about
Adaptive Biotechnologies Corp?
Write Note

Adaptive Biotechnologies Corp
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Adaptive Biotechnologies Corp
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Adaptive Biotechnologies Corp
NASDAQ:ADPT
Cash & Cash Equivalents
$38.1m
CAGR 3-Years
-32%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Cash & Cash Equivalents
$4.6B
CAGR 3-Years
-27%
CAGR 5-Years
30%
CAGR 10-Years
24%
Danaher Corp
NYSE:DHR
Cash & Cash Equivalents
$2.6B
CAGR 3-Years
1%
CAGR 5-Years
-29%
CAGR 10-Years
-4%
Mettler-Toledo International Inc
NYSE:MTD
Cash & Cash Equivalents
$71.6m
CAGR 3-Years
-27%
CAGR 5-Years
-10%
CAGR 10-Years
-6%
Agilent Technologies Inc
NYSE:A
Cash & Cash Equivalents
$1.8B
CAGR 3-Years
8%
CAGR 5-Years
0%
CAGR 10-Years
-3%
IQVIA Holdings Inc
NYSE:IQV
Cash & Cash Equivalents
$1.6B
CAGR 3-Years
2%
CAGR 5-Years
13%
CAGR 10-Years
9%
No Stocks Found

Adaptive Biotechnologies Corp
Glance View

Market Cap
692.1m USD
Industry
Life Sciences Tools & Services

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. The company is headquartered in Seattle, Washington and currently employs 858 full-time employees. The company went IPO on 2019-06-27. The firm is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform combines a suite of chemistry, biology and machine learning to generate clinical immunomics data to decode the adaptive immune system. Its commercial research products include immunoSEQ and immunoSEQ T-MAP. immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA). Its clonoSEQ diagnostic test detects and monitors the number of cancer cells that are present in a patient’s body during and after treatment, known as minimal residual disease (MRD). The company uses its T cell receptor (TCR)-Antigen Map to develop research solutions and diagnostic products, such as immunoSEQ T-MAP and T-Detect. The company also focuses on developing immune-mediated therapies in oncology and other disease areas.

ADPT Intrinsic Value
6.89 USD
Undervaluation 32%
Intrinsic Value
Price

See Also

What is Adaptive Biotechnologies Corp's Cash & Cash Equivalents?
Cash & Cash Equivalents
38.1m USD

Based on the financial report for Sep 30, 2024, Adaptive Biotechnologies Corp's Cash & Cash Equivalents amounts to 38.1m USD.

What is Adaptive Biotechnologies Corp's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
-13%

Over the last year, the Cash & Cash Equivalents growth was -57%. The average annual Cash & Cash Equivalents growth rates for Adaptive Biotechnologies Corp have been -32% over the past three years , -13% over the past five years .

Back to Top